Search

Your search keyword '"Franzosi, M. G."' showing total 118 results

Search Constraints

Start Over You searched for: Author "Franzosi, M. G." Remove constraint Author: "Franzosi, M. G."
118 results on '"Franzosi, M. G."'

Search Results

1. Are all people with diabetes and cardiovascular risk factors or microvascular complications at very high risk? Findings from the Risk and Prevention Study

6. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial

7. Are all people with diabetes and cardiovascular risk factors or microvascular complications at very high risk? Findings from the Risk and Prevention Study

8. Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke

10. Valsartan for prevention of recurrent atrial fibrillation (New England Journal of Medicine (2009) 360, (1606-1617))

11. Multiethnic Meta-Analysis of Genome-Wide Association Studies in >100 000 Subjects Identifies 23 Fibrinogen-Associated Loci but No Strong Evidence of a Causal Association Between Circulating Fibrinogen and Cardiovascular Disease

12. Association between C reactive protein and coronary heart disease : mendelian randomisation analysis based on individual participant data

14. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group

15. MEDICAL SCIENCE. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction

17. Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis. Results of the GISSI-2 data base. The Ad hoc Working Group of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-2 Data Base.

25. Use of beta-blocking agents in secondary prevention after myocardial infarction: a case for evidence-based medicine?

26. The prognostic value of predischarge quantitative two-dimensional echocardiographic measurements and the effects of early lisinopril treatment on left ventricular structure and function after acute myocardial infarction in the GISSI-3 Trial.

29. Common variants at 10 genomic loci influence hemoglobin A1C levels via glycemic and nonglycemic pathways (Diabetes (2010) 59, (3229-3239))

31. Hemostatic factors and family history of thrombosis in patients with a myocardial infarct: a case-control study. The participants in GISSI-2-Efrim. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico | Fattori dell'emostasi e storia familiare di trombosi in pazienti con infarto del miocardio: studio caso-controllo. I patecipanti al GISSI-2-Efrim

32. Common variants at 10 genomic loci influence hemoglobin A1C levels via glycemic and nonglycemic pathways (Diabetes (2010) 59, (3229-3239))

33. GISSI-3 - EFFECTS OF LISINOPRIL AND TRANSDERMAL GLYCERYL TRINITRATE SINGLY AND TOGETHER ON 6-WEEK MORTALITY AND VENTRICULAR-FUNCTION AFTER ACUTE MYOCARDIAL-INFARCTION

36. Comparison of fondaparinux and enoxaparin in acute coronary syndromes

37. Common variants at 10 genomic loci influence hemoglobin A1Clevels via glycemic and nonglycemic pathways (Diabetes (2010) 59, (3229-3239))

38. GISSI-2: mortality plus extensive left-ventricular damage as "end-point".

41. Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial

42. Criteria for the choice of anticoagulant therapy for the prevention of stroke in patients with atrial fibrillation early after the marketing of direct oral anticoagulants in Italy.

43. A multicenter observational study on the management of hyperglycemia in patients with acute coronary syndrome.

44. Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events.

45. Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart.

46. [Reperfusion after acute myocardial infarct with fibrinolytic therapy o combination reduced fibrinolytic therapy and a glycoprotein IIb/IIIa inhibitor: the GUSTO V study].

47. [PROCARDIS: A current approach to the study of the genetics of myocardial infarct].

48. [Susceptibility gene to infarct: a review of the literature].

49. Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial.

50. [Hirudin is superior to heparin in reducing cardiovascular mortality, infarct and refractory angina in patients with unstable angina or myocardial infarct without elevation of the ST tract].

Catalog

Books, media, physical & digital resources